ERBB2 and blue cone monochromacy: New agents inhibiting PARP, CDK 4/6, PI3K, ILGF-1, estrogen pathways, HDAC, and HER2+ receptors and downstream effects, are being combined with traditional options such as radiation and surgery to develop new strategies to treat BCM (12).